Q-MedAB: Invitation to Q1 report conference call

Q-MedAB: Invitation to Q1 report conference call

Time: Wednesday, May 3, 2007 at 13.30 p.m. CET.
To join the conference: 
Swedish dial in number: + 46 (0)8 505 201 14
UK dial in number: +44 (0)20 7162 0125
Q-Med participants:        
Bengt Ågerup, CEO
Erika Kjellberg Eriksson, CFO
Madelene Sandgren, Director Investor Relations and Corporate
Communications
The press release for Q-Med AB's Q1 report will be released
approximately
12 o´ clock noon on May 3, 2006.
The slide presentation will be available at:
www.q-med.com/Investors/Presentations
A recorded version of the presentation will be available for seven
working days on tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031
4064, access code: 74 69 17.

Queries should be addressed to:
Madelene Sandgren, Director Investor Relations and Corporate
Communications,
Tel: + 46 (0) 70-974 90 15

Q-MedAB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily
medical implants. The majority of the products are based on the
company's patented technology, NASHA™ for the production of stabilized
non-animal hyaluronic acid.  The product portfolio today contains:
RESTYLANE for the filling out of lips and facial wrinkles and for facial
contouring, DUROLANE, for the treatment of osteoarthritis of the hip and
knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR, (a
malformation of the urinary bladder) in children, ZUIDEX, for the
treatment of stress urinary incontinence in women and SOLESTA, for the
treatment of fecal incontinence. Sales are made through the company's
own subsidiaries or distributors in over 70 countries. Q-Med today has
just over 600 co-workers, with approximately 400 at the company's head
office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Large Cap segment of the OMX Nordic Stock Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names
within the RESTYLANE family are trademarks that belong to Q-Med AB.